Integrated metabolomics and lipidomics study of patients with atopic dermatitis in response to dupilumab.

ABSTRACT:

Background

Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases. Dupilumab, a monoclonal antibody that targets the interleukin (IL)-4 and IL-13 receptors, has been widely used in AD because of its efficacy. However, metabolic changes occurring in patients with AD in response to dupilumab remains unknown. In this study, we integrated metabolomics and lipidomics analyses with clinical data to explore potential metabolic alterations associated with dupilumab therapeutic efficacy. In addition, we investigated whether the development of treatment side effects was linked to the dysregulation of metabolic pathways.

Methods

A total of 33 patients with AD were included in the current study, with serum samples collected before and after treatment with du

SUBMITTER: Zhang L 

PROVIDER: S-EPMC9632449 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature